Regeneron Pharmaceuticals Inc logo

REGN - Regeneron Pharmaceuticals Inc News Story

$516.62 -0.6  -0.1%

Last Trade - 14/05/21

Large Cap
Market Cap £39.22bn
Enterprise Value £38.64bn
Revenue £6.55bn
Position in Universe 223rd / 6851

UPDATE 1-Swiss gov't looks to boost domestic COVID-19 vaccine, therapy production

Wed 14th April, 2021 4:34pm
(Adds details, comment from Health Minister)
    ZURICH, April 14 (Reuters) - Switzerland will investigate
ways to strengthen domestic COVID-19 vaccine and drug
development and production, the government said on Wednesday,
reacting as global demand outstrips supply due to rising
infections at home and abroad.
    The government also announced it was setting aside $100
million to buy costly antibody therapies, including from
U.S.-based Regeneron  REGN.O  and Swiss drugmaker Roche  ROG.S ,
in part for those who are still unvaccinated but live in
households where somebody has been infected.
    Switzerland is home to Lonza  LONN.S  that makes drug
ingredients for Moderna's  MRNA.O  COVID-19 vaccine, but the
government has so far shied from direct capacity investments. 
    That could change with this new push, announced at a press
conference where officials also outlined easing of lockdown
measures despite rising infections.*:nZ8N2K901G 
    "This could clearly have to do with vaccines," Swiss Health
Minister Alain Berset told reporters of the new push. "We are
going to look into what we can do, what seems realistic and what
is wanted, to secure access for our entire population to these
    The $100 million Switzerland is now setting aside for the
treatments comes after Roche and Regeneron on Tuesday announced
trial results indicating their REGEN-COV antibody cocktail
helped prevent symptomatic infections, even among people who
live together with somebody with COVID-19. (
    "Experience shows that these treatments are a very good
thing," Berset said, adding that the antibody therapies have
been reserved. "These are very expensive treatments, but even
so, they're substantially cheaper than long-term intensive

 (Reporting by John Miller; editing by Brenna Hughes Neghaiwi)
 ((; +41 58 306 7734; Reuters
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.